Phase IV Open Label Study of the Effects of Secukinumab on Nail Psoriasis and non-invasive measures of enthesitis
Recruiting
18-99 years
All
Phase
4
40 participants needed
1 Location
Brief description of study
The purpose of this study is to determine how psoriatic nail disease is affected by secukinumab. Secukinumab (Cosentyx®) is a prescription medicine that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis, active psoriatic arthritis, and active ankylosing spondylitis in adults. While secukinumab has already been approved to treat psoriasis, the goal of this study is to look more closely at how it affects specific measures of psoriatic nail disease including imaging and patient reported measurements. Secukinumab is known as a biologic, and works by blocking the activity of a specific protein in the immune system, interleukin-17A, which is believed to be involved in psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Secukinumab will be given at the currently approved dose for psoriasis which is 300 mg subcutaneously (under the skin) every 4 weeks with a loading regimen of 300 mg at a first baseline visit and then at Weeks 1, 2, 3, and 4.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Nail Psoriasis
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
03 Sep 2024.
Study ID: 834149
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
